Biofrontera

Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Biofrontera reports Q1 recovery post cyberattack, eyes product expansion

Biofrontera Inc. navigated challenges in Q1 2024, with a cyberattack impacting revenues, but recovery and growth were evident by April 30, 2024.
The company's strategic strengths lie in cost reduction through renegotiations, successful fundraising efforts, and advancements in clinical trials and product development.
Opportunities abound for Biofrontera with upcoming product launches, FDA approvals, and a focus on operational efficiency and financial management to drive future profitability.
Addressing financial challenges and leveraging opportunities will be key for Biofrontera to sustain growth, enhance market position, and deliver value to stakeholders in the coming quarters.

Biofrontera reports robust Q2 sales growth and cost efficiencies

Biofrontera delivered strong sales growth and cost management in Q2 2024, improving financial performance.
While challenges like net losses persist, opportunities exist to leverage momentum for sustained growth.
The company's focus on operational efficiency and revenue expansion sets the stage for future success and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sphere 3D

Tivic Health Systems

3 penny stocks with low floats to watch as shares of ENSC stock skyrocket. The post 3 Low Float Penny Stocks To Watch After ENSC Stock Soared appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Low Float Penny Stocks To Watch After ENSC Stock Soared

WOBURN, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the first subject has been enrolled in a Phase 1 study to evaluate the safety and tolerability of photodynamic therapy (PDT) for the treatment of actinic keratosis (AK) using three tubes of Ameluz® together with the company's BF-RhodoLED® XL lamp. This open-label study is being conducted at eight sites and will enroll 100 subjects with mild-to-severe AK on the face and scalp.

Biofrontera Inc. Enrolls First Subject in Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz®

The stock price of Biofrontera Inc (NASDAQ: BFRI) increased by over 27% during intraday trading today. This is why it happened.

Biofrontera (BFRI) Stock: Why The Price Surged Today

WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the U.S. patent application number 17/234,490, titled “Illumination for Photodynamic Therapy,” that covers an innovative, pain-reducing illumination protocol for photodynamic therapy (PDT).

Biofrontera Inc. Announces Notice of Allowance for U.S. Patent on Innovative Illumination Protocol

WOBURN, MA., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI; BFRIW) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the closing of a private placement with a single institutional investor for the purchase of 2,857,143 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 2,857,143 shares of common stock. The combined purchase price for one share of common stock (or common stock equivalent) and a warrant to purchase one share of common stock was $5.25, priced at-the-market under Nasdaq rules. The warrants have an exercise price of $5.25 per share, will be immediately exercisable, and will expire five years from the issuance date.

Biofrontera Inc. Announces Closing of $15 Million Private Placement

Conference c all at 4:30 p.m. Eastern t ime today

Biofrontera Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

WOBURN, MA., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Biofrontera, Inc. (Nasdaq: BFRI; BFRIW), today announced today that it has entered into a securities purchase agreement with a single institutional investor for the purchase of 2,857,143 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 2,857,143 shares of common stock, in a private placement. The combined purchase price for one share of common stock (or common stock equivalent) and a warrant to purchase one share of common stock is $5.25, priced at-the-market under Nasdaq rules. The warrants have an exercise price of $5.25 per share, will be immediately exercisable, and will expire five years from the issuance date.

Biofrontera Inc. Pricing of $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Shares of Biofrontera Inc (NASDAQ: BFRI) jumped nearly 50% on Wednesday after Roth Capital said the stock is ready for a massive rally up. Analyst Jonathan Aschoff sees upside to $20 On Wednesday, Roth Capital's Jonathan Aschoff assumed coverage of the BFRI stock with a “buy” rating and a price target of $20 that represents […] The post Biofrontera stock news: Roth Capital sees a 300% upside appeared first on Invezz.

Biofrontera stock news: Roth Capital sees a 300% upside

Allied Esports Entertainment Inc

ReTo Eco-Solutions

Here's three penny stocks to watch right now The post Check These 3 Penny Stocks Out For Your Watchlist Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Check These 3 Penny Stocks Out For Your Watchlist Right Now

WOBURN, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, will report financial results for the three and nine months ended September 30, 2021 before the opening of the U.S. financial markets on Tuesday, November 30, 2021 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time to discuss those results and provide a business update.

Biofrontera Inc. to Report Third Quarter Financial Results on November 30, 2021

WOBURN, MA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today the start of a clinical study program focused on optimizing and expanding the market positioning of its in-licensed FDA-approved prescription drug Ameluz® for photodynamic therapy (PDT) in the United States. Site initiations for two upcoming studies are currently in progress with patient recruitment to start before the end of the year. The studies are being initiated and overseen by Biofrontera AG, an affiliate of the Company.

Biofrontera Kicks Off US Clinical Study Program for Ameluz®

WOBURN, MA., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (“Biofrontera” or the “Company”) (Nasdaq: BFRI; BFRIW), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the closing of its underwritten initial public offering of 3,600,000 units, each consisting of (i) one share of common stock and (ii) one warrant to purchase a share of common stock, at a public offering price per unit of $5.00. The underwriters exercised in full their option to purchase up to an additional 540,000 warrants. The warrants have an exercise price of $5.00 per share and are exercisable for a period of five years after the issuance date. The common stock and warrants are traded on the Nasdaq Capital Market under the ticker symbols “BFRI” and “BFRIW,” respectively.

Biofrontera Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Warrants

WOBURN, MA. , Oct. 28, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (“Biofrontera” or the “Company”) (Nasdaq: BFRI; BFRIW), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the pricing of its underwritten initial public offering of 3,600,000 units, each consisting of (i) one share of common stock and (ii) one warrant to purchase a share of common stock, at a public offering price per unit of $5.00. The warrants have an exercise price of $5.00 per share and are exercisable for a period of five years after the issuance date. All units are being offered by Biofrontera Inc. In addition, Biofrontera has granted the underwriters a 30-day option to purchase an additional 540,000 shares of its common stock and/or warrants to purchase up to an additional 540,000 of its common stock, at the initial public offering price, less the underwriting discounts and commissions.

Biofrontera Inc. Announces Pricing of $18.0 Million Initial Public Offering

News for Biofrontera Stock (BFRI)